Ekso Bionics (NASDAQ:EKSO) Coverage Initiated at StockNews.com

Stock analysts at StockNews.com initiated coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a note issued to investors on Sunday. The brokerage set a “hold” rating on the stock.

EKSO has been the subject of a number of other research reports. Lake Street Capital lowered their target price on shares of Ekso Bionics from $2.50 to $2.00 and set a “buy” rating for the company in a research note on Tuesday, October 29th. HC Wainwright decreased their price target on Ekso Bionics from $10.00 to $9.00 and set a “buy” rating for the company in a report on Tuesday, October 29th.

Ekso Bionics Stock Up 3.6 %

EKSO opened at $0.89 on Friday. Ekso Bionics has a fifty-two week low of $0.83 and a fifty-two week high of $3.13. The company has a debt-to-equity ratio of 0.28, a quick ratio of 1.77 and a current ratio of 2.81. The stock has a fifty day moving average of $1.10 and a 200-day moving average of $1.14. The company has a market capitalization of $19.51 million, a P/E ratio of -1.36 and a beta of 1.45.

Ekso Bionics (NASDAQ:EKSO) last issued its quarterly earnings results on Monday, October 28th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.02). The business had revenue of $4.13 million during the quarter, compared to the consensus estimate of $6.00 million. Ekso Bionics had a negative net margin of 62.95% and a negative return on equity of 83.09%. During the same quarter in the previous year, the business posted ($0.24) EPS. On average, equities analysts expect that Ekso Bionics will post -0.48 EPS for the current year.

Hedge Funds Weigh In On Ekso Bionics

A hedge fund recently raised its stake in Ekso Bionics stock. Kent Lake Capital LLC raised its stake in Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) by 322.3% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 596,050 shares of the company’s stock after purchasing an additional 454,892 shares during the period. Kent Lake Capital LLC owned 3.28% of Ekso Bionics worth $811,000 as of its most recent SEC filing. 6.42% of the stock is currently owned by institutional investors and hedge funds.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.